With all the uncertainty of COVID-19, we hope you are safe and in good health. Ozgene is still here to meet your research needs.

Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation.

 Back to publications

2020

J Exp Med. 2020 Feb 3;217(2). pii: e20181384. doi: 10.1084/jem.20181384.

Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation.

T Weng;J Huang;EJ Wagner;J Ko;M Wu;NE Wareing;Y Xiang;NY Chen;P Ji;JG Molina;KA Volcik;L Han;MD Mayes;MR Blackburn;S Assassi

University of Texas Health Science Center at Houston, Houston, TX. The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. The University of Texas Medical Branch at Galveston, Galveston, TX.

Service type: Knockout mice

Abstract

Systemic sclerosis (SSc; scleroderma) is a multisystem fibrotic disease. The mammalian cleavage factor I 25-kD subunit (CFIm25; encoded by NUDT21) is a key regulator of alternative polyadenylation, and its depletion causes predominantly 3'UTR shortening through loss of stimulation of distal polyadenylation sites. A shortened 3'UTR will often lack microRNA target sites, resulting in increased mRNA translation due to evasion of microRNA-mediated repression. Herein, we report that CFlm25 is downregulated in SSc skin, primary dermal fibroblasts, and two murine models of dermal fibrosis. Knockdown of CFIm25 in normal skin fibroblasts is sufficient to promote the 3'UTR shortening of key TGFβ-regulated fibrotic genes and enhance their protein expression. Moreover, several of these fibrotic transcripts show 3'UTR shortening in SSc skin. Finally, mice with CFIm25 deletion in fibroblasts show exaggerated skin fibrosis upon bleomycin treatment, and CFIm25 restoration attenuates bleomycin-induced skin fibrosis. Overall, our data link this novel RNA-processing mechanism to dermal fibrosis and SSc pathogenesis.

View Publication